What is HC Wainwright’s Estimate for LABT Q4 Earnings?

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report) – Stock analysts at HC Wainwright lifted their Q4 2026 earnings per share (EPS) estimates for shares of Lakewood-Amedex Biotherapeutics in a research report issued to clients and investors on Tuesday, November 17th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($0.21) per share for the quarter, up from their previous forecast of ($1.44). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is $1.61 per share. HC Wainwright also issued estimates for Lakewood-Amedex Biotherapeutics’ FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.92) EPS.

A number of other research firms have also commented on LABT. Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Read Our Latest Analysis on LABT

Lakewood-Amedex Biotherapeutics Price Performance

LABT opened at $0.24 on Thursday. The stock has a fifty day moving average of $0.80 and a 200-day moving average of $5.13. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.10).

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

Read More

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.